Measurement of an apoptotic product in the sera of breast cancer patients.
about
New Prognostic Biomarkers in Patients With Traumatic Brain InjuryTotal and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study.Circulating cell death products predict clinical outcome of colorectal cancer patientsSoluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.Serum levels of caspase-cleaved cytokeratin-18 and mortality are associated in severe septic patients: pilot studyDetection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury.Serum levels of caspase-cleaved cytokeratin-18 in patients with severe traumatic brain injury are associated with mortality: a pilot study.Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patientsBiomarker method validation in anticancer drug developmentMethod validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression.Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery.Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapyCell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunctionCytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.Serum efficacy biomarkers for oncology.Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients.The extracellular release of HMGB1 during apoptotic cell death.Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular CarcinomaDocetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122.Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis.Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.Role of Uremic Toxins on Apoptosis With Varying Periods of Hemodialysis.Association between serum levels of caspase-cleaved cytokeratin-18 and early mortality in patients with severe spontaneous intracerebral hemorrhage.High serum levels of caspase-cleaved cytokeratin-18 are associated with malignant middle cerebral artery infarction patient mortality.Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinomaResponse to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study
P2860
Q26768672-889C7968-DBD6-46EB-8D17-C6A81C57DC40Q33332059-27054A6C-6F0F-4A09-B51B-AA50D1D7080FQ33420106-6305F818-B5F3-42E5-9200-4C5A6E0B623BQ33787691-2F32B9AD-DF1A-4E07-8A60-C50A89E3230EQ34002666-A562DFED-098F-4755-9944-D4568955FB01Q34301831-44910F56-7AFC-4705-B5A3-5A776CF05C3BQ34359266-5DF314FD-B787-487E-A371-F4C9247C57E6Q35231584-87D86350-D9A3-446A-A022-E110F23C6885Q36177752-E66D7E7E-294B-4BD8-BE61-0F637B463E9CQ36484621-4784D92F-AC74-46C0-9880-BA3D5E10798CQ36611534-2B89E793-DB85-453F-B7A4-615B0777694BQ36897795-58CD388D-0597-4B24-8F3B-5218E2221102Q36980678-ECBC050D-0589-4BCC-9415-FF5C225CBA79Q37111059-F5700435-8885-489C-B8C6-B440B20BBAD6Q37119996-374831A9-AD4D-41A2-937D-AAAF91AE0BC7Q37278502-DF5E1B72-0A35-4FAF-A952-695DD5F66F8FQ37279896-086FB162-58C2-4A1E-9D6A-C823B2B3334EQ37287486-70EFA447-D229-476E-AA2D-DC2556A74CCBQ37724878-7D1C755B-58D5-432E-A869-F6BA292DA6BAQ37755150-7FB11369-E14C-437D-9C96-9C2E720228D6Q38212434-4152D45D-B20A-42D8-BA0D-1272B79F460BQ40253423-A933CCA3-2A6B-46EE-B314-41BD2E62F82DQ40463082-5A211E4D-62C1-419A-A142-33761809A7EAQ41191656-C44B8DB2-D904-4CF0-9C8A-63A2520BC88BQ41883096-B115AC61-C3E0-4122-84F9-338779685796Q42249715-D14DDE8A-1192-43BB-833F-C306B375E0B0Q46853359-A4921C9B-AA74-4CA2-B73E-C2B224D64E9EQ48594906-9D6CE6B5-5DE8-4A1D-AC67-6FF28116248BQ50043508-5F4DAF65-F10C-4125-A73B-C48C552C3C5BQ50893230-8DBC9D8B-043D-4019-BE7B-44E9A621BB87Q50962466-22D16618-67B6-4E85-9346-0F04BD0D3C6EQ52585124-CB6B815B-8B73-4A19-9E43-3D3C587EFFF8Q52638531-D71B6513-5B76-4023-A945-A0F1845E3061Q52714347-0BC7F222-0182-47CA-A854-5F5C0A87BF5DQ57482211-195FC0F0-B7B8-4CF2-97BB-695091C09FBEQ57725217-EA999DD6-9E74-49FC-9B37-7323F1A6A6B9
P2860
Measurement of an apoptotic product in the sera of breast cancer patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Measurement of an apoptotic product in the sera of breast cancer patients.
@en
Measurement of an apoptotic product in the sera of breast cancer patients.
@nl
type
label
Measurement of an apoptotic product in the sera of breast cancer patients.
@en
Measurement of an apoptotic product in the sera of breast cancer patients.
@nl
prefLabel
Measurement of an apoptotic product in the sera of breast cancer patients.
@en
Measurement of an apoptotic product in the sera of breast cancer patients.
@nl
P2093
P1476
Measurement of an apoptotic product in the sera of breast cancer patients.
@en
P2093
P304
P356
10.1016/S0959-8049(02)00865-1
P577
2003-04-01T00:00:00Z